Literature DB >> 15576052

Application of the yeast Yarrowia lipolytica as a model to analyse human pathogenic mutations in mitochondrial complex I (NADH:ubiquinone oxidoreductase).

Stefan Kerscher1, Ljuban Grgic, Aurelio Garofano, Ulrich Brandt.   

Abstract

While diagnosis and genetic analysis of mitochondrial disorders has made remarkable progress, we still do not understand how given molecular defects are correlated to specific patterns of symptoms and their severity. Towards resolving this dilemma for the largest and therefore most affected respiratory chain enzyme, we have established the yeast Yarrowia lipolytica as a eucaryotic model system to analyse respiratory chain complex I. For in vivo analysis, eYFP protein was attached to the 30-kDa subunit to visualize complex I and mitochondria. Deletions strains for nuclear coded subunits allow the reconstruction of patient alleles by site-directed mutagenesis and plasmid complementation. In most of the pathogenic mutations analysed so far, decreased catalytic activities, elevated K(M) values, and/or elevated I(50) values for quinone-analogous inhibitors were observed, providing plausible clues on the pathogenic process at the molecular level. Leigh mutations in the 49-kDa and PSST homologous subunits are found in regions that are at the boundaries of the ubiquinone-reducing catalytic core. This supports the proposed structural model and at the same time identifies novel domains critical for catalysis. Thus, Y. lipolytica is a useful lower eucaryotic model that will help to understand how pathogenic mutations in complex I interfere with enzyme function.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15576052     DOI: 10.1016/j.bbabio.2004.07.006

Source DB:  PubMed          Journal:  Biochim Biophys Acta        ISSN: 0006-3002


  8 in total

Review 1.  Eukaryotic complex I: functional diversity and experimental systems to unravel the assembly process.

Authors:  Claire Remacle; M Rosario Barbieri; Pierre Cardol; Patrice P Hamel
Journal:  Mol Genet Genomics       Date:  2008-06-18       Impact factor: 3.291

2.  Introducing a novel human mtDNA mutation into the Paracoccus denitrificans COX I gene explains functional deficits in a patient.

Authors:  Simona Lucioli; Klaus Hoffmeier; Rosalba Carrozzo; Alessandra Tessa; Bernd Ludwig; Filippo M Santorelli
Journal:  Neurogenetics       Date:  2005-11-12       Impact factor: 2.660

3.  High-efficiency biolistic transformation of Chlamydomonas mitochondria can be used to insert mutations in complex I genes.

Authors:  Claire Remacle; Pierre Cardol; Nadine Coosemans; Mauricette Gaisne; Nathalie Bonnefoy
Journal:  Proc Natl Acad Sci U S A       Date:  2006-03-14       Impact factor: 11.205

4.  Pathogenic mutations in NUBPL affect complex I activity and cold tolerance in the yeast model Yarrowia lipolytica.

Authors:  Andrew E Maclean; Virginia E Kimonis; Janneke Balk
Journal:  Hum Mol Genet       Date:  2018-11-01       Impact factor: 5.121

5.  Insights into the pathogenic character of a common NUBPL branch-site mutation associated with mitochondrial disease and complex I deficiency using a yeast model.

Authors:  Mateusz M Wydro; Janneke Balk
Journal:  Dis Model Mech       Date:  2013-07-04       Impact factor: 5.758

6.  Chlamydomonas reinhardtii as a plant model system to study mitochondrial complex I dysfunction.

Authors:  Nitya Subrahmanian; Andrew David Castonguay; Thea Aspelund Fatnes; Patrice Paul Hamel
Journal:  Plant Direct       Date:  2020-02-03

7.  Characterization of clinically identified mutations in NDUFV1, the flavin-binding subunit of respiratory complex I, using a yeast model system.

Authors:  Febin Varghese; Erwan Atcheson; Hannah R Bridges; Judy Hirst
Journal:  Hum Mol Genet       Date:  2015-09-07       Impact factor: 6.150

8.  Investigating the function of [2Fe-2S] cluster N1a, the off-pathway cluster in complex I, by manipulating its reduction potential.

Authors:  James A Birrell; Klaudia Morina; Hannah R Bridges; Thorsten Friedrich; Judy Hirst
Journal:  Biochem J       Date:  2013-11-15       Impact factor: 3.857

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.